Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uriphytol versus tamsulosin for benign prostatic obstruction at KCMC
PACTR202304488683045Phase 2Unknown
- Sponsor
- Iphytos
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tamsulosin and finasteride in benign prostatic hyperplasia (BPH) and bladder outlet obstruction (BOO) (3 arms), sponsored by Iphytos. Primary endpoint: Relief in lower urinary tract symptoms. Status: unknown.
02
Drugs
tamsulosinfinasteride
03
Conditions
benign prostatic hyperplasia (BPH)bladder outlet obstruction (BOO)
Beyond the preview
Go deeper on PACTR202304488683045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202304488683045.